scholarly journals The protein tyrosine phosphatase receptor type H, PTPRH, is differentially expressed in the primary tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Protein Tyrosine Phosphatase ◽  
Tyrosine Phosphatase ◽  
Growth Factor Receptor ◽  
Differentially Expressed ◽  
Receptor Type ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Protein Tyrosine ◽  
Pediatric Solid Tumors

Trastuzumab, a monoclonal antibody targeted against the human epidermal growth factor receptor 2 (HER2) is utilized for the treatment of human breast cancer (1, 2), but a complete understanding of how tumor signal transduction is modulated by trastuzumab treatment is lacking. By mining published and public microarray and gene expression data (3, 4) from the primary tumors of patients treated with trastuzumab, we found that the protein tyrosine phosphatase receptor type H, encoded by PTPRH, was among the genes most differentially expressed in the primary tumors of patients treated with trastuzumab, and expressed at lower levels in the tumors of patients treated with trastuzumab. Thus, the use of trastuzumab in patients with breast cancer is associated with decreased primary tumors expression of a protein tyrosine phosphatase whose deficiency in pediatric solid tumors defines a risk-phenotype (5) and whose expression is decreased in colorectal cancer (6).

Trastuzumab-treated Invasive Lobular Carcinoma patients have a differently expressed protein tyrosine phosphatase receptor type H, PTPRH

2021 ◽  
Author(s):  
James D. Klingensmith
Keyword(s):  
Protein Tyrosine Phosphatase ◽  
Tyrosine Phosphatase ◽  
Lobular Carcinoma ◽  
Growth Factor Receptor ◽  
Receptor Type ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Protein Tyrosine ◽  
Pediatric Solid Tumors ◽  
Trastuzumab Therapy

Trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), is used to treat human breast cancer1,2. However, a thorough knowledge of how trastuzumab therapy modulates tumor signal transduction is inadequate. We discovered that the protein tyrosine phosphatase receptor type H, encoded by PTPRH, was among the genes most differentially expressed in the primary tumors of patients treated with trastuzumab, and expressed at lower levels in the tumors of patients treated with trastuzumab, by mining published and public microarray and gene expression data3,4 from the primary tumors of patients treated with trastuzumab. Thus, trastuzumab treatment in breast cancer patients is linked to lower primary tumor expression of a protein tyrosine phosphatase, whose deficit in pediatric solid tumors identifies a risk-phenotype and whose expression is reduced in colorectal cancer.

Trastuzumab-treated Invasive Lobular Carcinoma patients have a differently expressed protein tyrosine phosphatase receptor type H, PTPRH

2021 ◽  
Author(s):  
Mairead Paul ◽  
Brandon Weston ◽  
Oliwier Morin
Keyword(s):  
Protein Tyrosine Phosphatase ◽  
Tyrosine Phosphatase ◽  
Lobular Carcinoma ◽  
Growth Factor Receptor ◽  
Receptor Type ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Protein Tyrosine ◽  
Pediatric Solid Tumors ◽  
Trastuzumab Therapy

Trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), isused to treat human breast cancer1,2. However, a thorough knowledge of how trastuzumab therapy modulatestumor signal transduction is inadequate. We discovered that the protein tyrosine phosphatase receptor type H,encoded by PTPRH, was among the genes most differentially expressed in the primary tumors of patientstreated with trastuzumab, and expressed at lower levels in the tumors of patients treated with trastuzumab, bymining published and public microarray and gene expression data3,4 from the primary tumors of patientstreated with trastuzumab. Thus, trastuzumab treatment in breast cancer patients is linked to lower primarytumor expression of a protein tyrosine phosphatase, whose deficit in pediatric solid tumors identifies a riskphenotypeand whose expression is reduced in colorectal cancer.

scholarly journals SYK, CSK and FYN are differentially expressed in the primary tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tyrosine Kinases ◽  
Growth Factor Receptor ◽  
Protein Tyrosine Kinases ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Transcriptional Responses ◽  
Primary Tumors ◽  
Protein Tyrosine

The mechanism of action underlying trastuzumab (Herceptin) function is ascribed to binding of the Fab region of trastuzumab to the extracellular domain of the human epidermal growth factor receptor (HER2) (1). The transcriptional responses that follow signals transduced after trastuzumab binding of HER2 are less well understood. Protein tyrosine kinases are one major class of cellular components utilized in the transduction of signals from the cell surface to the nucleus. We mined published microarray and multiplexed gene expression data (2-5) to understand in an unbiased fashion genes most differentially expressed in the primary tumors of breast cancer patients treated with trastuzumab. We observed significantly increased and differential expression of multiple protein tyrosine kinases in the primary tumors of patients with breast cancer, including SYK, CSK and FYN. These data document previously undescribed up-regulation of protein tyrosine kinases following treatment with trastuzumab in patients with breast cancer.

scholarly journals DCC is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Messenger Rna ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Deleted In Colorectal Cancer

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray and gene expression data (3, 4) to discover in an unbiased manner the most striking transcriptional features of trastuzumab treatment. We identified the deleted in colorectal cancer locus DCC (5, 6) as among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of DCC messenger RNA than did patients not treated with trastuzumab, and a single administration of trastuzumab was sufficient to result in differential expression of DCC in primary tumors of the breast, demonstrating that a gene encoding for a netrin receptor, cellular machinery utilized for axon guidance in the central nervous system (5-9), is transcriptionally induced in primary tumors of the breast following treatment with trastuzumab.

scholarly journals The placental growth factor (PGF) is differentially expressed in the primary tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Placental Growth Factor ◽  
Differentially Expressed ◽  
Expression Data ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Epidermal Growth ◽  
The Brain

Trastuzumab, a monoclonal antibody targeted against the human epidermal growth factor receptor 2 (HER2) is utilized for the treatment of human breast cancer (1, 2), but a complete understanding of how tumor signal transduction is modulated by trastuzumab treatment is lacking. By mining published and public microarray and gene expression data (3, 4) from the primary tumors of patients treated with trastuzumab, we found that the placental growth factor, encoded by PGF was among the genes most differentially expressed in the primary tumors of patients treated with trastuzumab, and expressed at lower levels in the tumors of patients treated with trastuzumab. Thus, the use of trastuzumab in patients with breast cancer is associated with increased expression of a growth factor that is chemotactic, angiogenic (5) and important for growth of blood vessels in the brain (6).

scholarly journals MATK is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Cancer Patients ◽  
Messenger Rna ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray and gene expression data (3, 4) to discover in an unbiased manner the most striking transcriptional features of trastuzumab treatment. We identified the megakaryocyte-associated tyrosine kinase MATK (5, 6) as among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of MATK messenger RNA than did patients not treated with trastuzumab, and a single administration of trastuzumab was sufficient to result in differential expression of MATK in primary tumors of the breast, demonstrating that a platelet-expressed tyrosine kinase (5, 6) that interacts with the receptor for the stem cell factor (7) is likely transcriptionally induced in primary tumors of the breast by trastuzumab.

scholarly journals NEUROD4 is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Messenger Rna ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Unbiased Manner

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray and gene expression data (3, 4) to discover in an unbiased manner the most significant transcriptional changes associated with trastuzumab treatment. We identified NEUROD4 among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of NEUROD4 messenger RNA than did patients not treated with trastuzumab, and a single administration of trastuzumab was sufficient to result in differential expression of NEUROD4 in primary tumors of the breast, demonstrating increased expression of a transcription factor with neurogenic potential (5, 6) as a direct transcriptional consequence of treatment with trastuzumab.

scholarly journals Adropin, produced by the energy homeostasis associated gene ENHO is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Messenger Rna ◽  
Energy Homeostasis ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray and gene expression data (3, 4) to discover in an unbiased manner the most significant transcriptional changes associated with trastuzumab treatment. We identified ENHO among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of ENHO messenger RNA than did patients not treated with trastuzumab, and a single administration of trastuzumab was sufficient to result in differential expression of ENHO in primary tumors of the breast, demonstrating increased expression of a molecule involved in regulation of glucose and lipid metabolism and whose expression is modulated by high-fat diet (5) as a direct transcriptional consequence of treatment with trastuzumab.

Sign in / Sign up

Export Citation Format

Share Document